Obsidian Therapeutics Inc(OBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OBX Obsidian Therapeutics Inc

休市中 09-11 16:00:00 EDT

17.80

+0.64

+3.73%

盘后17.80

+0.000.00%

19:30 EDT

最高18.49	最低17.17	成交量39.28万
今开17.23	昨收17.16	日振幅7.69%
总市值10.99亿	流通市值10.58亿	总股本6,173万
成交额710.61万	换手率0.66%	流通股本5,946万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OBX","market":"US","secType":"STK","nameCN":"Obsidian Therapeutics Inc","latestPrice":17.8,"timestamp":1789156800000,"preClose":17.16,"halted":0,"volume":392799,"hourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.8,"latestTime":"19:30 EDT","volume":11,"amount":195.8,"timestamp":1789169406852,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03729603729603733,"floatShares":59462058,"shares":61727211,"eps":-4.246465,"marketStatus":"休市中","change":0.64,"latestTime":"09-11 16:00:00 EDT","open":17.23,"high":18.49,"low":17.17,"amount":7106056.790778,"amplitude":0.076923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.246465,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":17.16,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.8,"latestTime":"19:30 EDT","volume":11,"amount":195.8,"timestamp":1789169406852,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1815614577188283},"requestUrl":"/m/hq/s/OBX","defaultTab":"news","newsList":[{"id":"1180960798","title":"Obsidian Therapeutics提交招股说明书，涉及最多29,164,045股普通股转售","url":"https://stock-news.laohu8.com/highlight/detail?id=1180960798","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180960798?lang=zh_cn&edition=full","pubTime":"2026-08-29 05:13","pubTimestamp":1787951593,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics Inc已向美国证券交易委员会提交了一份招股说明书，内容涉及出售股东转售最多29,164,045股普通股。此次提交的招股说明书并未涉及公司自身的资金募集行为，而是旨在为股东提供一个合规的转售平台。值得关注的是，Obsidian Therapeutics专注于细胞疗法的开发，其核心研发管线正处於临床前及早期临床阶段。此类公司的股价对融资及股东活动尤为敏感，本次提交的招股书亦将成为投资者近期评估该公司股票供需关系的关键参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160444967","title":"Obsidian Therapeutics宣布：晚期黑色素瘤新药Amsoki-Cel (Obx-115) 关键注册队列首例患者成功入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160444967","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160444967?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:06","pubTimestamp":1785927982,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics公司今日重磅宣布，其针对晚期黑色素瘤的细胞疗法——Amsoki-Cel（原名Obx-115），在1/2期Agni-01研究的注册导向队列中，已成功完成首例患者入组。这一里程碑事件，标志着该创新疗法正式迈入关键性临床开发阶段，为全球黑色素瘤患者带来了全新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.obsidiantx.com","stockEarnings":[{"period":"1week","weight":0.0583},{"period":"1month","weight":-0.3643},{"period":"3month","weight":-0.6438},{"period":"ytd","weight":-0.6438}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Obsidian Therapeutics, Inc.是一家于2026年4月10日在特拉华州注册成立的生物制药公司。该公司专注于开发小分子超氧化物歧化酶（SOD）模拟物，旨在通过减少副作用来改善癌症放射治疗的效果。Obsidian目前的产品组合包括一种泛NOS抑制剂，其主要研发项目正处于乳腺癌联合治疗的I/II期临床试验阶段。该公司还开发用于治疗实体瘤的工程化肿瘤浸润淋巴细胞（TIL）疗法。Obsidian的专有cytoDRiVE平台能够通过药物响应结构域控制蛋白质功能，初期重点开发基于该平台的TIL细胞疗法。Obsidian的主要候选产品是一种新型的基因工程自体TIL细胞疗法，目前正在进行治疗晚期黑色素瘤和非小细胞肺癌的临床试验。","exchange":"NASDAQ","name":"Obsidian Therapeutics Inc","nameEN":"Obsidian Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Obsidian Therapeutics Inc(OBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Obsidian Therapeutics Inc(OBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Obsidian Therapeutics Inc,OBX,Obsidian Therapeutics Inc股票,Obsidian Therapeutics Inc股票老虎,Obsidian Therapeutics Inc股票老虎国际,Obsidian Therapeutics Inc行情,Obsidian Therapeutics Inc股票行情,Obsidian Therapeutics Inc股价,Obsidian Therapeutics Inc股市,Obsidian Therapeutics Inc股票价格,Obsidian Therapeutics Inc股票交易,Obsidian Therapeutics Inc股票购买,Obsidian Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Obsidian Therapeutics Inc(OBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Obsidian Therapeutics Inc(OBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}